Management of mild hypertension in adults

BMJ (Online)

Volumn 355, Issue , 2016, Pages

  Viera, Anthony J ^a   Hawes, Emily M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AWARENESS; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE CONTROL; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE QUALITY; HOME MONITORING; HUMAN; HYPOTENSION; INCIDENCE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); THERAPY DELAY; ADULT; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HYPERTENSION; LIFESTYLE; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; LIFE STYLE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84997654176     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i5719     Document Type: Review

References (93)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-60. doi:10. 1016/S0140-6736(12)61766-8 pmid:23245609.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. doi:10. 1016/S0140-6736(02)11911-8 pmid:12493255.
3. Mozaffarian D, Benjamin EJ, Go AS, et al. Writing Group Members American Heart Association Statistics Committee Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016;133:e38-360. doi:10. 1161/CIR. 0000000000000350 pmid:26673558.
4. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002;287:1003-10. doi:10. 1001/jama. 287. 8. 1003 pmid:11866648.
5. Weaver CG, Clement FM, Campbell NR, et al. Alberta Kidney Disease Network and the Interdisciplinary Chronic Disease Collaboration. Healthcare costs attributable to hypertension: Canadian populationbased cohort study. Hypertension 2015;66:502-8. doi:10. 1161/HYPERTENSIONAHA. 115. 05702 pmid:26169049.
6. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292. doi:10. 1161/01. cir. 0000441139. 02102. 80 pmid:24352519.
7. Yoon SS, Gu Q, Nwankwo T, Wright JD, Hong Y, Burt V. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension 2015;65:54-61. doi:10. 1161/HYPERTENSIONAHA. 114. 04012 pmid:25399687.
8. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-86. doi:10. 1056/NEJMoa010273 pmid:11519501.
9. Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U. S. by improvements in use of clinical preventive services. Am J Prev Med 2010;38:600-9. doi:10. 1016/j. amepre. 2010. 02. 016 pmid:20494236.
10. U. S. Preventive Services Task Force. Screening for high blood pressure: U. S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007;147:783-6. doi:10. 7326/0003-4819-147-11-200712040-00009 pmid:18056662.
11. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, Blood Institute Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. doi:10. 1001/jama. 289. 19. 2560 pmid:12748199.
12. U. S. Preventive Services Task Force. Final Recommendation Statement. Hypertension in adults: screening. 2015. http://www. uspreventiveservicestaskforce. org/Page/Document/RecommendationStatementFinal/high-blood-pressure-in-adultsscreening.
13. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U. S. Preventive Services Task Force. Ann Intern Med 2015;162:192-204. doi:10. 7326/M14-1539 pmid:25531400.
14. Jones DW, Appel LJ, Sheps SG, Roccella EJ, Lenfant C. Measuring blood pressure accurately: new and persistent challenges. JAMA 2003;289:1027-30. doi:10. 1001/jama. 289. 8. 1027 pmid:12597757.
15. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005;111:697-716. doi:10. 1161/01. CIR. 0000154900. 76284. F6 pmid:15699287.
16. Reeves RA. The rational clinical examination. Does this patient have hypertension? How to measure blood pressure. JAMA 1995;273:1211-8. doi:10. 1001/jama. 1995. 03520390071036 pmid:7707630.
17. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 2011. https://www. nice. org. uk/guidance/cg127.
18. Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review. Am J Med 2015;128:14-20. doi:10. 1016/j. amjmed. 2014. 07. 021 pmid:25107387.
19. Verberk WJ, Kroon AA, Kessels AG, et al. The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. J Hypertens 2006;24:1541-8. doi:10. 1097/01. hjh. 0000239289. 87141. b6 pmid:16877956.
20. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension?JAMA 1988;259:225-8. doi:10. 1001/jama. 1988. 03720020027031 pmid:3336140.
21. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005;46:508-15. doi:10. 1016/j. jacc. 2005. 03. 070 pmid:16053966.
22. Imai Y, Ohkubo T, Sakuma M, et al. Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: a prospective observation in a cohort from Ohasama, northern Japan. Blood Press Monit 1996;1:251-4. pmid:10226238.
23. Staessen JA, Thijs L, Fagard R, et al. Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999;282:539-46. doi:10. 1001/jama. 282. 6. 539 pmid:10450715.
24. Ohkubo T, Hozawa A, Nagai K, et al. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens 2000;18:847-54. doi:10. 1097/00004872-200018070-00005 pmid:10930181.
25. Franklin SS, Thijs L, Hansen TW, et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a metaanalysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012;59:564-71. doi:10. 1161/HYPERTENSIONAHA. 111. 180653 pmid:22252396.
26. Stergiou GS, Asayama K, Thijs L, et al. International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension 2014;63:675-82. doi:10. 1161/HYPERTENSIONAHA. 113. 02741 pmid:24420553.
27. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in whitecoat versus sustained mild hypertension: a 10-year followup study. Circulation 1998;98:1892-7. doi:10. 1161/01. CIR. 98. 18. 1892 pmid:9799210.
28. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and whitecoat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159-69. doi:10. 1016/j. jacc. 2015. 09. 007 pmid:26564592.
29. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64. doi:10. 1016/S0140-6736(00)03307-9 pmid:11130523.
30. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001;37:869-74. doi:10. 1161/01. HYP. 37. 3. 869 pmid:11244010.
31. Marchant I, Nony P, Cucherat M, et al. The global risk approach should be better applied in French hypertensive patients: a comparison between simulation and observation studies. PLoS One 2011;6:e17508. doi:10. 1371/journal. pone. 0017508 pmid:21408615.
32. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20. doi:10. 1001/jama. 2013. 284427 pmid:24352797.
33. Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014;160:499-503. doi:10. 7326/M13-2981 pmid:24424788.
34. Wright JT Jr, Williamson JD, Whelton PK, et al. SPRINT Research Group. A randomized trial of intensive versus standard bloodpressure control. N Engl J Med 2015;373:2103-16. doi:10. 1056/NEJMoa1511939 pmid:26551272.
35. Myers MG, Valdivieso MA. Use of an automated blood pressure recording device, the BpTRU, to reduce the "white coat effect" in routine practice. Am J Hypertens 2003;16:494-7. doi:10. 1016/S0895-7061(03)00058-X pmid:12799100.
36. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT results to the U. S. adult population. J Am Coll Cardiol 2016;67:463-72. doi:10. 1016/j. jacc. 2015. 10. 037 pmid:26562046.
37. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 2012;8:CD006742. pmid:22895954.
38. Sundström J, Arima H, Jackson R, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184-91. doi:10. 7326/M14-0773 pmid:25531552.
39. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet 1980;1:1261-7. pmid:6104081.
40. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985;291:97-104. doi:10. 1136/bmj. 291. 6488. 97 pmid:2861880.
41. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64. doi:10. 1001/jama. 1991. 03460240051027 pmid:2046107.
42. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Ann N Y Acad Sci 1978;304:267-92. doi:10. 1111/j. 1749-6632. 1978. tb25604. x pmid:360921.
43. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52. doi:10. 1056/NEJM199803053381003 pmid:9486993.
44. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97. doi:10. 1046/j. 1523-1755. 2002. 00213. x pmid:11849464.
45. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40. doi:10. 1016/S0140-6736(07)61303-8 pmid:17765963.
46. Ruggenenti P, Fassi A, Ilieva AP, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51. doi:10. 1056/NEJMoa042167 pmid:15516697.
47. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J. DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328:495. doi:10. 1136/bmj. 37970. 629537. 0D pmid:14960504.
48. Asselbergs FW, Diercks GF, Hillege HL, et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16. doi:10. 1161/01. CIR. 0000146378. 65439. 7A pmid:15492322.
49. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-54. doi:10. 1161/01. CIR. 102. 15. 1748 pmid:11023927.
50. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. doi:10. 1136/bmj. 317. 7160. 703 pmid:9732337.
51. MacMahon S, Sharpe N, Gamble G, et al. PART-2 Collaborative Research Group. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000;36:438-43. doi:10. 1016/S0735-1097(00)00736-1 pmid:10933355.
52. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. doi:10. 1136/bmj. b1665 pmid:19454737.
53. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67. doi:10. 1016/S0140-6736(15)01225-8 pmid:26724178.
54. Karmali KN, Ning H, Goff DC, Lloyd-Jones DM. Identifying individuals at risk for cardiovascular events across the spectrum of blood pressure levels. J Am Heart Assoc 2015;4:e002126. doi:10. 1161/JAHA. 115. 002126 pmid:26391134.
55. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alphablocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42:239-46. doi:10. 1161/01. HYP. 0000086521. 95630. 5A pmid:12925554.
56. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. doi:10. 1001/jama. 288. 23. 2981 pmid:12479763.
57. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-71. doi:10. 1001/jama. 1979. 03300230018021 pmid:490882.
58. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-52. doi:10. 1001/jama. 1970. 03170330025003 pmid:4914579.
59. Savage PJ, Pressel SL, Curb JD, et al. SHEP Cooperative Research Group. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998;158:741-51. doi:10. 1001/archinte. 158. 7. 741 pmid:9554680.
60. Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990;15:348-60. doi:10. 1161/01. HYP. 15. 4. 348 pmid:2318517.
61. Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, adverse biochemical effects. BMJ 1990;300:975-8. doi:10. 1136/bmj. 300. 6730. 975 pmid:2344503.
62. Flack JM, Cushman WC. Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 1996;101(3A):53S-60S. doi:10. 1016/S0002-9343(96)00268-9 pmid:8876475.
63. Freis ED, Thomas JR, Fisher SG, et al. Effects of reduction in drugs or dosage after long-term control of systemic hypertension. Am J Cardiol 1989;63:702-8. doi:10. 1016/0002-9149(89)90255-5 pmid:2646896.
64. Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239. doi:10. 1016/j. jacc. 2013. 05. 019 pmid:23747642.
65. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32:3-15. doi:10. 1097/HJH. 0000000000000065 pmid:24270181.
66. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern?Arch Intern Med 2000;160:685-93. doi:10. 1001/archinte. 160. 5. 685 pmid:10724055.
67. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. doi:10. 1016/S0140-6736(02)08089-3 pmid:11937178.
68. Eckel RH, Jakicic JM, Ard JD, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(Suppl 2):S76-99. doi:10. 1161/01. cir. 0000437740. 48606. d1 pmid:24222015.
69. Sacks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10. doi:10. 1056/NEJM200101043440101 pmid:11136953.
70. Obarzanek E, Proschan MA, Vollmer WM, et al. Individual blood pressure responses to changes in salt intake: results from the DASHSodium trial. Hypertension 2003;42:459-67. doi:10. 1161/01. HYP. 0000091267. 39066. 72 pmid:12953018.
71. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004;(3):CD004937. pm id:15266549.
72. Fagard RH. Effects of exercise, diet and their combination on blood pressure. J Hum Hypertens 2005;19(Suppl 3):S20-4. doi:10. 1038/sj. jhh. 1001956 pmid:16302006.
73. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002;136:493-503. doi:10. 7326/0003-4819-136-7-200204020-00006 pmid:11926784.
74. Gordon T, Doyle JT. Alcohol consumption and its relationship to smoking, weight, blood pressure, blood lipids. The Albany Study. Arch Intern Med 1986;146:262-5. doi:10. 1001/archinte. 1986. 00360140068008 pmid:3947186.
75. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38:1112-7. doi:10. 1161/hy1101. 093424 pmid:11711507.
76. Leiter LA, Abbott D, Campbell NR, Mendelson R, Ogilvie RI, Chockalingam A. Lifestyle modifications to prevent and control hypertension. Recommendations on obesity and weight loss. CMAJ 1999; 160(Suppl 9):S7-12. pmid:10333848.
77. Mulrow CD, Chiquette E, Angel L, et al. Dieting to reduce body weight for controlling hypertension in adults 2. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Cochrane Database Syst Rev 2000;(2):CD000484. pmid:10796721.
78. Getchell WS, Svetkey LP, Appel LJ, Moore TJ, Bray GA, Obarzanek E. Summary of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Curr Treat Options Cardiovasc Med 1999;1:295-300. doi:10. 1007/s11936-999-0024-6 pmid:11096495.
79. Appel LJ, Moore TJ, Obarzanek E, et al. DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24. doi:10. 1056/NEJM199704173361601 pmid:9099655.
80. Appel LJ, Champagne CM, Harsha DW, et al. Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003;289:2083-93. pmid:12709466.
81. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-6. doi:10. 1016/S0140-6736(01)06710-1 pmid:11728544.
82. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-7. pmid:9934341.
83. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002;24:1347-57, discussion 1346. doi:10. 1016/S0149-2918(02)80039-X pmid:12240784.
84. van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens 2008;26:145-53. doi:10. 1097/HJH. 0b013e32826308b4 pmid:18090552.
85. Qvarnström M, Kahan T, Kieler H, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 2013;69:1955-64. doi:10. 1007/s00228-013-1555-z pmid:23857249.
86. O'Connor PJ, Sperl-Hillen JAM, Johnson PE, et al. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES, et al, eds. Advances in patient safety: from research to implementation (Volume 2: Concepts and Methodology). Agency for Healthcare Research and Quality (US), 2005.
87. Institute of Medicine. A population-based policy and systems change approach to prevent and control hypertension. National Academies Press, 2010.
88. Walsh JM, McDonald KM, Shojania KG, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care 2006;44:646-57. doi:10. 1097/01. mlr. 0000220260. 30768. 32 pmid:16799359.
89. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA 2013;310:699-705. doi:10. 1001/jama. 2013. 108769 pmid:23989679.
90. Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357. doi:10. 1097/01. hjh. 0000431740. 32696. cc pmid:23817082.
91. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3:e000718. doi:10. 1161/JAHA. 113. 000718 pmid:24721801.
92. Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ 2004;329:145. doi:10. 1136/bmj. 38121. 684410. AE pmid:15194600.
93. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004;(2):CD004804. pmid:15106262.